Rubraca targets DNA repair mechanisms in cancer cells, offering a therapeutic benefit in BRCA mutation-associated cancers.

Therapeutic Effect of Rubraca

Rubraca is a PARP inhibitor that exerts its therapeutic effect by interfering with the repair of DNA damage in cancer cells. This leads to the accumulation of DNA damage in tumor cells, particularly those harboring BRCA mutations, and results in tumor cell death. Its primary use is in the maintenance treatment of BRCA mutation-positive ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy. By exploiting the concept of synthetic lethality, Rubraca enhances the anti-tumor effect and potentially prolongs progression-free survival in patients.